Proteins are synthesized as linear chains of amino acids, but their true functional complexity emerges after translation. Post-translational modifications (PTMs) introduce chemical changes to proteins, profoundly influencing their structure, function, and interactions. For antibodies, these modifications play a critical role in their diversity, specificity, and therapeutic potential.
Types of Post-Translational Modifications
1. Chain Additions
Glycosylation: Antibodies frequently undergo N-linked glycosylation at the Fc domain. This process regulates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation.
O-linked glycosylation and glycation, while less common, can influence antigen binding and serum half-life.
Sulfation and Cysteinylation: These modifications occur in the variable domain and affect antigen binding and immune signaling.
2. Chain Trimming
C-terminal Lysine Clipping: A process that occurs during antibody manufacturing, lysine clipping can impact antibody charge heterogeneity, affecting stability and function.
3. Amino Acid Modifications
Cyclization: Conversion of the N-terminal glutamine to pyroglutamic acid can enhance antibody stability and resistance to degradation.
Deamidation and Isomerization: These age-related changes can reduce antigen-binding affinity and functional efficacy.
Oxidation: Commonly affects methionine and tryptophan residues, potentially impairing Fc receptor binding.
Carbamylation: Alters the charge and structural integrity of antibodies, influencing their activity.
4. Disulfide Bond Alterations
Disulfide Scrambling: Disruption of hinge-region disulfide bonds can weaken antibody structural stability, reducing functional potency.
The Role of PTMs in Antibody Function
Enhancing Antigen Recognition
PTMs in antibody variable domains modulate binding affinity and specificity. For example, glycosylation in the Fab region can either enhance or hinder antigen binding, depending on the modification's context.
Regulating Effector Functions
Fc-mediated activities, such as ADCC and complement-dependent cytotoxicity (CDC), are highly sensitive to PTMs. Controlled glycosylation patterns in the Fc region, such as the absence of fucose, can significantly increase ADCC activity.
Microheterogeneity and Functional Diversity
Each antibody molecule can exist as a population of variants due to PTMs, creating microheterogeneity. This diversity introduces differences in potency, stability, and activity, which are particularly relevant in therapeutic antibody development.
PTMs in Antibody Therapeutics
Manufacturing Challenges and Opportunities: Initially considered a manufacturing nuisance, PTMs are now leveraged to enhance antibody properties. Strategies include controlled glycosylation to optimize therapeutic efficacy and engineering stable disulfide bonds to improve antibody durability.
Tailored Therapeutics: PTMs are being intentionally manipulated to create next-generation antibodies with enhanced or novel functionalities, such as bispecific antibodies and antibody-drug conjugates (ADCs).
Related: Recombinant Protein Expression in Mammalian Cells & E.coli
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
